FDA Approval Makes Breyanzi Third CAR-T Therapy in NHL

With the FDA’s approval of Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) earlier this month, there are now three chimeric antigen receptor T cell (CAR-T) therapies to treat a certain type of non-Hodgkin’s lymphoma (NHL). A Zitter Insights poll shows that payers do not anticipate its approval as having much of an impact on their management of the space.

On Feb. 5, the FDA approved Breyanzi for the treatment of adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B.

Breyanzi — previously known as liso-cel, the shortened version of its non-proprietary name — joins Yescarta (axicabtagene ciloleucel) from Gilead Sciences Inc. unit Kite Pharma, Inc. and Novartis Pharmaceuticals Corp.’s Kymriah (tisagenlecleucel) as the three CAR-T therapies in NHL.

For the Managed Care Oncology Index: Q2 2020, between June 1, 2020, and June 30, 2020, Zitter Insights polled 51 commercial payers with 129.6 million covered lives. Those with 96% of lives anticipated that they would manage Breyanzi to label.

Payers said that Breyanzi would need to have a 15% to 16% reduction in its wholesale acquisition cost from the WACs of the other two CAR-Ts for members to have access to the new agent. Breyanzi launched with a list price of $410,300 for the one-time treatment compared with $373,000 for Yescarta and Kymriah in NHL.

Zitter Insights also polled 102 oncologists during the same time frame. Approximately half said they did not anticipate administering Breyanzi, slightly more than those with the same response for Yescarta and Kymriah (see chart below). Of oncologists administering the CAR-Ts, more expected to do so in an inpatient setting as opposed to an outpatient one.

For more information on the Zitter data, contact Jill Brown Kettler at jbrown@aishealth.com.

SOURCE: Zitter Insights, Managed Care Oncology Index: Q2 2020.

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy (formerly called Specialty Pharmacy News) since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at HemAware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-radar-on-specialty-pharmacy-Another-Immunotherapy-Indication-Will-Be-Withdrawn.jpg
November 18

FDA Grants Interchangeable Status to Humira Biosimilar, but Certain Factors May Hamper Its, Other Adalimumabs’ Uptake

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-radar-on-drug-benefits-OptumRx-Spotlights-Two-Drugs-That-Treat-Rare-Liver-Diseases.jpg
November 18

Oncologists Show Interest in Prescribing New CML STAMP Inhibitor Scemblix

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/10/WordPress-Featured-Image-RADAR-on-Drug-Benefits-Eli-Lilly-Pounces-on-Flailing-Aduhelm-With-Competing-Drug.jpg
November 18

Eli Lilly Pounces on Flailing Aduhelm With Competing Drug

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today